US FDA grants ODD to Immix Biopharma’s NXC-201 for multiple myeloma
With ODD, NXC-201 is now eligible for seven years of US market exclusivity in the US upon regulatory…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
24 Aug 23
With ODD, NXC-201 is now eligible for seven years of US market exclusivity in the US upon regulatory…
24 Aug 23
The funding, which follows the firm’s launch with a $100m Series A financing in March this year, will…
24 Aug 23
Under the terms of the agreement, Aardvark Therapeutics will have the global development and commercialisation rights to ADAIR…
24 Aug 23
The expansion significantly boosts cell therapy capabilities and serves as a complementary addition to suspension and adhesion viral…
24 Aug 23
Funding from Wellcome will further broaden Vaxxas’ diverse clinical pipeline of next-generation vaccines to include Typhoid fever
24 Aug 23
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators. We are continuing the study until…
23 Aug 23
The funding under Project NextGen includes $1bn to BARDA partners for vaccine clinical trials, $326m to Regeneron for…
23 Aug 23
The trial compared Retevmo against physician's choice of the MKIs vandetanib or cabozantinib as an initial treatment and…
23 Aug 23
The approval was based on the findings from the Phase 3 CheckMate -76K trial in which Opdivo lowered…
23 Aug 23
The American biotechnology company is now submitting applications for its XBB.1.5 Covid vaccine candidate to regulatory agencies all…